表纸
市场调查报告书

倦怠感:开发平台分析

Fatigue - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品编码 192586
出版日期 内容资讯 英文 40 Pages
订单完成后即时交付
价格
Back to Top
倦怠感:开发平台分析 Fatigue - Pipeline Review, H2 2019
出版日期: 2019年08月30日内容资讯: 英文 40 Pages
简介

所谓倦怠感(疲劳感·疲惫·没精神·无感情等)是指肉体或精神性疲惫虚弱化的状态。主要的前兆·症状有肌肉痛和淋巴节的疼痛,慢性(长期的)疲劳,晕眩,头痛,过敏性,食欲不振等。

本报告提供全球各国治疗倦怠感所用的开发中产品之开发情形相关分析,提供您产品开发·上市的最新趋势,及临床实验各阶段产品一览,主要企业简介,主要药物概要,最新的产业趋势等资讯。

目录

简介

  • 分析范围

倦怠感概要

治疗药的开发

  • 倦怠感开发中产品:概要
  • 倦怠感开发中产品:比较分析

企业开发中的治疗药

开发中产品概况

  • 后期阶段的产品
  • 临床阶段的产品
  • 初期阶段的产品

企业开发中的产品

治疗药的开发企业

  • Biovista Inc.
  • Dimerix Bioscience Pty Ltd
  • Hemispherx Biopharma, Inc.
  • Merz Pharmaceuticals GmbH
  • MultiCell Technologies, Inc.
  • Teva Pharmaceutical Industries Limited

治疗药的评估

  • 单剂产品
  • 组合产品
  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

  • (lofepramine hydrochloride + phenylalanine)
  • armodafinil
  • DMX-400
  • MRZ-9547
  • rintatolimod
  • Small Molecule for Chronic Fatigue Syndrome

最新开发平台趋势

暂停中的计划

产品开发的里程碑

  • 主要消息和新闻稿

附录

图表一览

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11363IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fatigue - Pipeline Review, H2 2019, provides an overview of the Fatigue (Central Nervous System) pipeline landscape.

Fatigue also referred to as tiredness, exhaustion, lethargy, listlessness, and describes a physical and/or mental state of being tired and weak. Signs and symptoms include aching or sore muscles, painful lymph nodes, chronic (long-term) tiredness, dizziness, headache, irritability and loss of appetite.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fatigue - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Fatigue (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fatigue (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 3, 1, 3 and 2 respectively.

Fatigue (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fatigue (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Fatigue (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fatigue (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fatigue (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fatigue (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fatigue (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fatigue (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fatigue - Overview
  • Fatigue - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Fatigue - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fatigue - Companies Involved in Therapeutics Development
    • Aoxing Pharmaceutical Company Inc
    • Helsinn Group
    • K-Pax Pharmaceuticals Inc
    • Merz Pharma GmbH & Co KgaA
    • MultiCell Technologies Inc
    • Resolys Bio Inc
  • Fatigue - Drug Profiles
    • (lofepramine hydrochloride + phenylalanine) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anamorelin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Chronic Pain and Fatigue - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • caffeine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTDP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KPAX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MRZ-9547 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • phenylbutyrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLS-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fatigue - Dormant Projects
  • Fatigue - Product Development Milestones
    • Featured News & Press Releases
      • Jun 14, 2010: MultiCell Retains CDSS To Manage MCT-125 Phase IIb Clinical Trial For PMSF In UK
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Fatigue, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Fatigue - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019
  • Fatigue - Pipeline by Helsinn Group, H2 2019
  • Fatigue - Pipeline by K-Pax Pharmaceuticals Inc, H2 2019
  • Fatigue - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2019
  • Fatigue - Pipeline by MultiCell Technologies Inc, H2 2019
  • Fatigue - Pipeline by Resolys Bio Inc, H2 2019
  • Fatigue - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Fatigue, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top